To join GLP-1 Connect, visit About Inspire Founded in 2005, Inspire is the worlds largest online community for patients and caregivers
More recently, in March 2024, Wegovy was This approval followed promising results from novo Nordisks SELECT trial, which followed 17,604 adults with obesity or overweight and cardiovascular disease but no history of diabetes
However, women managing both conditions need more frequent monitoring and may need coordinated care between endocrinology and gynecology
This common question arises among patients starting glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound)
This is when many women see a "whoosh" effect, where weeks of hidden progress suddenly become visible
Long-acting ones (liraglutide, dulaglutide, exenatide weekly, semaglutide) keep working for at least 24 hours [2]